Suven Life Sciences’ NCE ‘SUVN-3031’ has commenced Phase 1 clinical trial in USA. SUVN-G3031 - a potent, selective, brain penetrant and orally active Histamine H3 antagonist for the treatment of cognitive dysfunction associated with Alzheimer ’s disease / Schizophrenia has completed all the preclinical, safety and early toxicological studies, GLP toxicological studies and was submitted for Investigational New Drug Application (IND) to conduct Phase 1 clinical trial with the indication for Cognition in Alzheimer’s Disease under 505(1) of the Federal Food, Drug and Cosmetic Act (FDCA).
Based on the IND ‘A Single Center, Double-blind, Placebo-controlled, Randomized, Phase 1 Study to Evaluate the safety, Tolerability, and Pharmacokinetics of SUVN-G3031 after Single Ascending Doses and Multiple Ascending Doses in Healthy Male Subjects’ for Cognition in Alzheimer’s Disease is underway in USA.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.
